Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.

Détails

ID Serval
serval:BIB_30851676B0A7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment.
Périodique
Cytotherapy
Auteur⸱e⸱s
Gannon P.O., Harari A., Auger A., Murgues C., Zangiacomi V., Rubin O., Ellefsen Lavoie K., Guillemot L., Navarro Rodrigo B., Nguyen-Ngoc T., Rusakiewicz S., Rossier L., Boudousquié C., Baumgaertner P., Zimmermann S., Trueb L., Iancu E.M., Sempoux C., Demartines N., Coukos G., Kandalaft L.E.
ISSN
1477-2566 (Electronic)
ISSN-L
1465-3249
Statut éditorial
Publié
Date de publication
12/2020
Peer-reviewed
Oui
Volume
22
Numéro
12
Pages
780-791
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Several studies report on Good Manufacturing Process (GMP)-compliant manufacturing protocols for the ex vivo expansion of tumor-infiltrating lymphocytes (TILs) for the treatment of patients with refractory melanoma and other solid malignancies. Further opportunities for improvements in terms of ergonomy and operating time have been identified.
To enable GMP-compliant TILs production for adoptive cell therapy needs, a simple automated and reproducible protocol for TILs manufacturing with the use of a closed system was developed and implemented at the authors' institution.
This protocol enabled significant operating time reduction during TILs expansion while allowing the generation of high-quality TILs products.
A simplified and efficient method of TILs expansion will enable the broadening of individualized tumor therapy and will increase patients' access to state-of-the-art TILs adoptive cell therapy treatment.
Mots-clé
Good Manufacturing Practice (GMP), Swissmedic, adoptive cell therapy (ACT), immunotherapy, manufacturing, tumor-infiltrating lymphocytes (TILs)
Pubmed
Web of science
Création de la notice
20/10/2020 13:42
Dernière modification de la notice
06/01/2021 7:25
Données d'usage